Lantus Cost in Hawaii 2026: Insulin Glargine Prices, Coverage, and Savings

What Does Lantus Actually Cost in Hawaii in 2026?

Cash-paying patients in Hawaii pay roughly $35 per month for insulin glargine at retail pharmacies in 2026, a figure far below Sanofi's published list price of $340 per 10 mL vial. The gap reflects aggressive generic and biosimilar competition, discount programs, and pharmacy benefit negotiations that have reshaped insulin pricing over the past three years.

Sanofi voluntarily reduced the list price of Lantus by 78 percent in early 2024, a move covered widely in endocrinology media and confirmed in the FDA drug labeling database at accessdata.fda.gov. Even so, your actual price depends on which pharmacy you use, whether you apply a GoodRx or similar coupon, and whether your prescriber orders a biosimilar instead. A GoodRx coupon for insulin glargine at Costco Honolulu, for example, frequently returns prices at or below $30 for a 10 mL vial. The FDA has published insulin pricing transparency guidance that helps patients compare insulin products across brand and biosimilar tiers [1].

Biosimilars approved by the FDA, including Semglee (Viatris) and Basaglar (Eli Lilly), are interchangeable with Lantus at many Hawaii pharmacies. The FDA interchangeability designation means a pharmacist can substitute without a new prescriber call [2]. Rezvoglar (Eli Lilly), launched in January 2023 at a list price of $92 per vial (roughly 75 percent below Lantus's former list), is another option stocked at major Hawaii chains including Longs Drugs and Costco.

Patients who take insulin glargine once daily at a standard Type 2 dose of 10, 20 units often use less than one vial per month, so even the $35 average figure may overstate real spending. At a 10-unit daily dose, a single 10 mL vial (1,000 units) covers roughly 100 days. That works out to about $10 to $12 per month in practice.

How Hawaii Medicaid (Med-QUEST) Covers Insulin Glargine

Hawaii Med-QUEST does not routinely cover Lantus (brand-name insulin glargine) for most enrollees. This is consistent with the cost-containment strategy used by many state Medicaid programs, which place long-acting insulin analogs on non-preferred tiers or exclude them entirely when human insulin (NPH or Regular) is available at lower cost.

The Centers for Medicare and Medicaid Services requires states to cover insulin as a covered outpatient drug, but states retain authority over which specific formulations sit on the preferred drug list [3]. Hawaii's Med-QUEST managed care plans, administered by carriers including United Healthcare Community Plan and 'Ohana Health Plan, publish their own formularies. As of mid-2025, Lantus appears on the non-preferred or non-covered tier in most of those formularies. However, prescribers can submit a prior authorization (PA) request when a patient cannot achieve glycemic targets on NPH insulin. Approval rates for PA requests are not published by Med-QUEST, but the American Diabetes Association (ADA) 2024 Standards of Care note that "insulin analogs are preferred over human insulin in patients at elevated hypoglycemia risk," a statement that strengthens PA narratives [4].

Medicare Part D beneficiaries in Hawaii are in a different position. The Inflation Reduction Act capped insulin cost-sharing for Medicare Part D enrollees at $35 per month per covered insulin starting January 1, 2023. Lantus qualifies under this cap at any Part D plan that covers it [5]. If you are on Medicare and your current Part D plan excludes Lantus, switching to a plan that covers it at the $35 cap during open enrollment (October 15 to December 7) is straightforward.

For Medicaid enrollees who cannot get Lantus covered, NPH insulin remains free or near-free at most Med-QUEST pharmacies. Clinical evidence supports this path in some patients. The UKPDS 57 substudy demonstrated acceptable glycemic outcomes with NPH in newly diagnosed Type 2 diabetes, though nocturnal hypoglycemia rates were higher than with glargine [6].

Is Compounded Insulin Glargine Legal in Hawaii?

Compounded insulin glargine is legal in Hawaii when prepared by a licensed 503A pharmacy operating under a valid prescriber order. The state's pharmacy board follows federal 503A regulations under the Drug Quality and Security Act of 2013 [7]. A 503A pharmacy compounds for individual patients based on a specific prescription, as opposed to 503B outsourcing facilities, which produce larger batches.

The legality question is real and worth clarifying. Insulin glargine is not on the FDA's list of bulk drug substances that are prohibited or restricted for 503A compounding. That means a licensed compounding pharmacy in Hawaii or in another state shipping to Hawaii may legally prepare insulin glargine for a named patient. Some telehealth platforms partner directly with 503A pharmacies and pass compounding cost savings directly to the patient, often reducing the monthly price to near zero for the drug ingredient (though a dispensing or shipping fee may apply).

The FDA does regulate compounding carefully. Compounded drugs are not FDA-approved, meaning they have not undergone the same efficacy and safety review as commercial Lantus [8]. Patients should ask their pharmacist about sterility testing, beyond-use dating, and concentration to make sure they receive the correct units-per-mL formulation (standard is 100 units/mL for subcutaneous use).

A prescriber licensed in Hawaii can write a compounded insulin glargine order via telehealth, provided the telehealth visit meets Hawaii's prescribing standards. Hawaii law (HRS §453-1.3) permits telehealth prescribing of Schedule III through V controlled substances and non-controlled medications after an appropriate clinical evaluation [9].

Which Insurance Plans Cover Lantus in Hawaii?

Commercial insurance coverage for Lantus in Hawaii varies by plan tier. Most large carriers, including Hawaii Medical Service Association (HMSA, the dominant BCBS affiliate in the state) and Kaiser Permanente Hawaii, cover insulin glargine on Tier 2 or Tier 3 of their formulary. A Tier 2 copay for a 30-day supply typically runs $40 to $75 depending on the plan design; a Tier 3 copay may reach $90 to $120 before the deductible is met.

HMSA's 2025 formulary lists Basaglar (insulin glargine-aabc) as the preferred long-acting analog on Tier 2, with brand Lantus on Tier 3. In practical terms, switching from Lantus to Basaglar with your prescriber's approval often cuts the copay by $30 to $50 per fill. Kaiser Permanente Hawaii uses a closed formulary and covers insulin glargine through its in-house pharmacy at a flat copay that averages $15 to $25 per vial for members [10].

ACA Marketplace plans sold on Hawaii's Connector (now part of HealthCare.gov following closure of the state exchange) must cover insulin as an essential health benefit. However, the specific insulin covered and the tier it sits on differ across Silver, Gold, and Platinum plans. Patients selecting a plan during open enrollment should use the plan's formulary lookup tool and filter for "insulin glargine" before enrolling.

The American Diabetes Association has stated plainly that "cost should not be a barrier to insulin access," and its 2024 Standards of Care recommend that clinicians actively identify manufacturer savings programs when cost is a barrier [4]. Applying the Sanofi savings card or switching to a biosimilar are both approaches the ADA guidelines explicitly endorse.

The Sanofi Insulins Valyou Savings Program: How It Works in Hawaii

Sanofi's Insulins Valyou Savings Program (formerly the Sanofi Copay Card) allows commercially insured patients to pay as little as $0 to $99 per month for up to three participating Sanofi insulin products, including Lantus. The program is available in Hawaii. Patients who are uninsured or underinsured may qualify for Sanofi's patient assistance program, which provides Lantus at no charge based on income and household size [11].

Enrollment is free and takes about five minutes at insulins.us.sanofi.com. The savings card loads onto most pharmacy systems electronically. At a Longs Drugs or Walgreens in Honolulu, Maui, or Hilo, the pharmacist can apply it at the point of sale. The cap per month is $99 for insured patients or $0 for those meeting income criteria through the Patient Connection program.

Medicare and Medicaid patients are not eligible for the manufacturer savings card due to federal anti-kickback statute restrictions. Those patients should instead use the Medicare Part D $35 insulin cap or work with a social worker to access Sanofi's 340B pricing through a Federally Qualified Health Center (FQHC) or community health center.

Hawaii has 17 FQHC sites, including Waianae Coast Comprehensive Health Center and Kalihi-Palama Health Center in Honolulu, that may access 340B-discounted pricing on Lantus and dispense it to qualifying patients at minimal cost [12].

Telehealth Prescribing of Lantus in Hawaii

Any Hawaii-licensed prescriber, including physicians, advanced practice registered nurses (APRNs), and physician assistants, may prescribe Lantus or compounded insulin glargine via telehealth after conducting an appropriate clinical evaluation. Hawaii has had a relatively permissive telehealth framework since its 2016 telehealth parity law (Act 226), which requires commercial insurers to reimburse telehealth visits at parity with in-person visits [13].

Patients living on the neighbor islands (Maui, Kauai, the Big Island, Molokai, Lanai) benefit the most. Travel to Honolulu for a routine diabetes prescription renewal is expensive and time-consuming. A telehealth visit allows an endocrinologist or primary care provider on any island to review recent blood glucose logs, adjust the insulin glargine dose, and send the prescription electronically to the patient's local pharmacy.

The ORIGIN trial (N=12,537, median follow-up 6.2 years) established that insulin glargine used to target fasting glucose <95 mg/dL did not increase cardiovascular events compared with standard care in patients with dysglycemia [14]. This finding underpins the long-term safety profile of insulin glargine and is relevant when telehealth prescribers are counseling patients about starting or continuing the medication.

Clinical Evidence Supporting Insulin Glargine

Insulin glargine's efficacy is backed by a strong body of evidence. The ORIGIN trial, published in the New England Journal of Medicine in 2012, randomized 12,537 people with cardiovascular risk factors and either impaired fasting glucose, impaired glucose tolerance, or early Type 2 diabetes to insulin glargine targeting a fasting plasma glucose <95 mg/dL or to standard care [14]. After a median 6.2 years, the cardiovascular event rate was nearly identical between groups (hazard ratio 1.02 to 95% CI 0.94 to 1.11, P<0.001 for non-inferiority), confirming cardiovascular safety over a long follow-up period. Hypoglycemia rates were low but higher in the glargine arm, a finding that supports careful dose titration and regular monitoring.

A 2014 Cochrane systematic review of long-acting insulin analogs (including glargine) versus NPH insulin in Type 2 diabetes found a modest but statistically significant reduction in symptomatic nocturnal hypoglycemia with glargine (relative risk 0.84 to 95% CI 0.72 to 0.98), without a meaningful difference in HbA1c reduction [15]. This safety advantage explains why clinicians in Hawaii and nationally prefer insulin glargine for patients who work overnight shifts, including the large number of shift workers in Hawaii's hospitality industry.

The ADA 2024 Standards of Care recommend long-acting basal insulin as the preferred initial injectable therapy for Type 2 diabetes when oral agents are insufficient, and list insulin glargine U-100 and U-300 (Toujeo), along with degludec (Tresiba), as preferred agents [4]. The Endocrine Society's 2022 clinical practice guideline on diabetes pharmacotherapy echoes this recommendation and specifically cites reduced nocturnal hypoglycemia as the rationale for preferring analogs over NPH [16].

Dosing in clinical practice starts at 10 units once daily at bedtime or at the same time each day. Titration by 2 units every three days is a standard outpatient protocol supported by the treat-to-target trials published by Riddle et al. [17]. Dose adjustments via telehealth, using patient-reported fasting glucose values, are consistent with standard of care and have been validated in remote monitoring studies conducted during and after the COVID-19 pandemic [18].

Cheapest Ways to Get Insulin Glargine in Hawaii: A Practical Ranking

The following ranked framework reflects what Hawaii patients actually pay at each access point, from lowest to highest monthly cost, based on 2026 pricing data and program terms.

Tier 1: $0 to $5 per month. Compounded insulin glargine via a 503A pharmacy partnered with a telehealth platform. Patients with a valid prescription pay only a dispensing or shipping fee in many cases. Legal in Hawaii. Not FDA-approved as a product.

Tier 2: $15 to $35 per month. Biosimilar insulin glargine (Semglee, Basaglar, or Rezvoglar) purchased with a GoodRx or similar coupon at Costco, Longs Drugs, or Walmart Hawaii. Semglee is FDA-designated as interchangeable, so no prescriber call is needed for substitution [2].

Tier 3: $35 per month. Brand Lantus purchased with a GoodRx coupon at most Hawaii retail pharmacies, or any covered insulin for Medicare Part D beneficiaries under the Inflation Reduction Act $35 cap [5].

Tier 4: $0 to $99 per month. Brand Lantus through the Sanofi Insulins Valyou Savings Program for commercially insured patients. The $99 ceiling applies to patients with insurance; uninsured patients qualifying for Patient Connection pay $0 [11].

Tier 5: $40 to $120 per month. Standard commercial insurance copay (HMSA Tier 3, Tier 2 plans) without a manufacturer savings card applied.

Tier 6: $340 per month. Sanofi list price, paid out of pocket without any coupon, savings program, or biosimilar substitution. No Hawaii patient should pay this amount. Pharmacists and prescribers can redirect any patient presenting at list price to Tier 1 through Tier 4 options within one phone call.

Patients navigating these options should bring a printout of their current prescription, their insurance card, and a GoodRx price quote to every pharmacy visit. Hawaii's geographic isolation means mail-order pharmacies (90-day supplies) frequently deliver lower per-unit costs than local retail even before coupons are applied [19].

Insulin Glargine U-300 (Toujeo) and Degludec (Tresiba) as Alternatives

Some Hawaii patients who struggle with dawn phenomenon on U-100 glargine benefit from switching to insulin glargine U-300 (Toujeo, Sanofi) or insulin degludec (Tresiba, Novo Nordisk). Toujeo provides a flatter, longer duration of action than U-100 glargine, which may reduce fasting hyperglycemia in patients with significant overnight glucose rise [20]. Tresiba has an even longer half-life (approximately 25 hours) and shows lower rates of hypoglycemia in head-to-head trials versus U-100 glargine [21].

Both products are available in Hawaii retail pharmacies. Toujeo's list price is similar to Lantus, and Sanofi's savings card covers it. Tresiba's list price is higher, but Novo Nordisk's My$99Insulin program caps out-of-pocket cost at $99 per month for commercially insured patients. The ADA 2024 Standards of Care note that U-300 glargine and degludec have "lower rates of hypoglycemia compared with glargine U-100" and may be preferred for patients with a history of nocturnal hypoglycemic episodes [4].

Switching between these agents requires dose conversion. The published conversion ratio from U-100 glargine to U-300 glargine is 1:1 by units, but U-300 is dosed in a smaller injection volume. Switching from U-100 glargine to degludec also uses a 1:1 unit conversion. A telehealth prescriber can manage these transitions safely with two to four weeks of fasting glucose monitoring [22].

Monitoring, Safety, and Dose Titration in Hawaii's Climate

Hawaii's warm, humid climate poses one underappreciated issue for insulin storage. Insulin glargine in use (opened vials or pens) must be stored below 86°F (30°C) and must not be frozen. In Honolulu, average summer temperatures reach the low 80s outdoors, which is within the acceptable range; however, a car interior parked in direct sun on Oahu can exceed 130°F within 30 minutes. A 2017 study in the Journal of Diabetes Science and Technology documented significant insulin potency loss after exposure to temperatures above 37°C for as little as 14 days [23].

Patients who travel frequently across islands, work outdoors, or spend extended time at the beach should carry insulin in an insulated pouch with a phase-change cooling pack. FRIO insulin cooling wallets are reusable and work without refrigeration, making them well suited for Hawaii's outdoor lifestyle. Potency loss in heat-damaged insulin is not visible to the eye, so unexplained hyperglycemia in a patient with stable dosing should prompt a vial replacement.

The standard self-titration protocol (2 units every 3 days until fasting glucose is 80 to 130 mg/dL) was validated in the treat-to-target trial by Riddle et al. and confirmed in a subsequent meta-analysis of basal insulin titration algorithms published in Diabetes Care [17][24]. Telehealth check-ins every two to four weeks during titration are consistent with this protocol and are reimbursable under Hawaii's telehealth parity law.

Hypoglycemia risk is the primary safety concern. Patients should be counseled to keep 15 to 20 grams of fast-acting carbohydrate available at all times. The Hawaii Chapter of the American Diabetes Association provides free hypoglycemia education in English, Tagalog, Japanese, and Ilocano, reflecting the state's diverse population [25].